A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...
In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...
Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are underway, and life-saving treatments have been developed.
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
The FDA approved Casgevy, a CRISPR/Cas9 gene-edited therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older last week. The market has reacted negatively to the ...
In this article, we will take a look at the Top 11 CRISPR Stocks to Invest in. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...
Pre-earnings options volume in Crispr Therapeutics (CRSP) is normal with calls leading puts 5:2. Implied volatility suggests the market is anticipating a move near 8.9%, or $4.56, after results are ...
CRISPR pioneer Jennifer Doudna, Ph.D., looks set to continue to push the boundaries of gene editing, as she announces plans to team up with life sciences giant Danaher to create a center focused on ...
A new study has revealed that the gene HMGN1 is a key driver of congenital heart defects (CHDs) in Down syndrome. Using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback